arrow
V

Vincenzo Quagliariello

istituto nazionale tumori-irccs-fondazione g. pascale
H指数:31
被引数:2,652

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Heart-Type Fatty Acid-Binding Protein (H-FABP) as a Candidate Adjunctive Biomarker for Immune Checkpoint Inhibitor-Related Cardiotoxicity: Linking Early Immune–Metabolic Myocardial Injury with Translational Cardio-Oncology

心脏型脂肪酸结合蛋白(H-FABP)作为免疫检查点抑制剂相关心脏毒性的候选辅助生物标志物:连接早期免疫-代谢心肌损伤与转化心血管肿瘤学

2026-05-300
OA
Evidence of Cardiotoxic Immune Activation by Triple Immune Checkpoint Blockade: A Translational Alert for Clinical Surveillance in Patients With Cancer

三重免疫检查点阻断诱导的心脏毒性免疫激活的证据:对癌症患者临床监测的转化警报

2026-03-150
OAAI
Healthcare Management in Cardio-Oncology, Clinical Strategies and Future Perspectives: A Narrative Review

心血管肿瘤学中的医疗管理、临床策略和未来展望:一篇叙事性综述

2025-10-150
OA
Fusobacterium Nucleatum in Colorectal Cancer: Relationship Among Immune Modulation, Potential Biomarkers and Therapeutic Implications

梭杆菌属核梭杆菌在结直肠癌中的作用:免疫调节、潜在生物标志物及治疗意义之间的关系

2025-10-060
OAAI
SGLT2i Dapagliflozin in primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +/- trastuzumab: rationale and design of the multicenter PROTECT trial

Greco, A.; Quagliariello, V.; Rizzo, G.; Tedeschi, A.; Schirinzi, S.; Turco, A.; Galiazzo, M.; Acquaro, M.; De Amicis, M.; Klersy, C.; et al. SGLT2i Dapagliflozin在以新辅助蒽环类药物为基础化疗(±曲妥珠单抗)治疗的乳腺癌患者中预防化疗诱导的心脏毒性的初级预防作用:多中心PROTECT试验的原理与设计。Cardiooncology 2025, 11, 79. [Google Scholar] [CrossRef]

2025-09-300
OAAI
SGLT2 Inhibitors in Cancer Patients: A Comprehensive Review of Clinical, Biochemical, and Therapeutic Implications in Cardio-Oncology

SGLT2抑制剂在癌症患者中的应用:心血管肿瘤学中临床、生物化学和治疗意义的全面综述

2025-05-160
OA